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Abstract DNA encoding the last 48 residues of the propart and the whole mature sequence of Plasmepsin II was inserted into the T7 dependent 
vector PET 3a for expression in E. coli. The resultant product was insoluble but accumulated at -20 mg/l of cell culture. Following solubilisation with 
urea, the zymogen was refolded and, after purification by ion-exchange chromatography, was autoactivated to generate mature Plasmepsin II. The 
ability of this enzyme to hydrolyse several chromogenic peptide substrates was examined; despite an overall identity of -35% to human renin, 
Plasmepsin II was not inhibited significantly by renin inhibitors. 
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1. Introduction 
During the blood borne stages of human infection by the 
malarial parasite Plasmodium falciparum, haemoglobin is di- 
gested in huge amounts as a source of nutrients to support 
metabolism. These reactions occur in a specialised, lysosome- 
like organelle, the digestive vacuole. Aspartic proteinase in- 
volvement in this processing has been established by de- 
monstrating that the first step in haemoglobin degradation is 
inhibited by pepstatin [l]. To date, two aspartic proteinases 
have been isolated from parasite food vacuoles [2] and the genes 
encoding both enzymes have been cloned and sequenced [3,4]. 
These enzymes have now been systematically renamed 
Plasmepsin I (replacing previous names Aspartic haemoglobi- 
nase I [2] and Plasmodium aspartic proteinase G [4]), and 
Plasmepsin II (replacing Aspartic haemoglobinase II [2] and 
Plasmodium aspartic proteinase D [4]). The Plasmepsin pro- 
teinases (EC3.4.23.38) thus represent important new targets for 
antimalarial chemotherapy. Elucidation of structure/activity 
relationships for both enzymes would facilitate the develop- 
ment of potent, specific inhibitors for potential application as 
drugs. Since only trivial amounts of material can be isolated 
directly from the parasites, production of each enzyme as a 
recombinant protein is essential. To this end, this report de- 
scribes the production of Plasmepsin II in E. coli in sufficiently 
high amounts to permit structural studies to be initiated to- 
gether with initial characterisation of the recombinant enzyme. 
high levels of expression of recombinant proteins as fusions with a 13 
amino acid leader sequence derived from the N-terminus of the T7 gene 
10 protein [5]. The sequence of a positive clone containing the Plasmep- 
sin II insert in the correct orientation was determined in its entirety to 
ensure that no mutations had been introduced during the polymerase 
chain reaction. 
2.2. Induction 
E. coli BLZl(DE3)pLysS cells transformed with the recombinant 
plasmid were grown to an Am of 0.4 in LB medium supplemented with 
150 &/ml ampicillin, and were induced by the addition of isopropyl-b- 
o-thiogalactopyranoside (IPTG) to a final concentration of 0.4 mM. 
Incubation was continued at 37“C for a further 2 h, at which time the 
cells were harvested by centrifugation (3,000 x g for 10 min) and resus- 
pended in TN buffer (50 mM Tris-HCl, pH 7.2, 0.15 M NaCl). Ly- 
sozyme was added (final concentration = 10 @ml) and the cells were 
lysed by freezing/thawing. 
2.3. Purification and refolding 
2. Materials and methods 
2.1. Cloning 
The gene encoding the last 48 residues of the pro region and the whole 
of the mature Plasmepsin II was amplified from the pBluescript KS+ 
clone 0075M [4] in a polymerase chain reaction using synthetic primers 
S-CCGGAATTCGGATCCGAACATTTAACTATTGG-3’ and the 
M 13 universal primer, 5’-GTAAAACGACGGCCAGT-3’. Following 
digestion of the amplified product with BamHI, fragments were ligated 
into pET3a (AMS Biotechnology, Milton Keynes, Bucks., UK) that 
had been cut with BamHI and phosphatase-treated. This vector permits 
Lysed cells (from 1 1 of culture) were diluted to 200 ml in TN 
buffer and stirred overnight at 4°C. Insoluble material containing the 
recombinant protein was pelleted by centrifugation at 16,000 x ,g for 30 
min. The pellet was resuspended in 200 ml buffer B (0.1 M Tris-HCl, 
pH 11 .O, 50 mM j?-mercaptoethanol) and stirred at 4°C for 4 h. Insol- 
uble material was re-pelleted and washed with a further 200 ml buffer 
B. After centrifugation, the washed pellet was resuspended in 10 ml 
buffer C (6 M urea. 0.1 M Tris-HCI. DH 8.0. 1 mM elvcine. 1 mM 
EDTA, 50 mM /?-mercaptoethanol) add stirred ovemKht at’4”C to 
solubilise the recombinant material. Residual insoluble material was 
removed by centrifugation at 28,0000x g for 2 h. The supematant 
containing recombinant protein was rapidly diluted into 2 1 buffer 
D (10 mM Tris-HCl, pH 8.5) and stirred at 25°C for a further 24 h to 
allow refolding of the recombinant protein. This solution was concen- 
trated to a volume of 30 ml using a Filtron Ultrasette, 5 kDa cut-off 
tangential flow concentrator (Flowgen Instruments Ltd, Sittingboume, 
Kent, UK) and the concentrate was loaded onto DEAE-cellulose Pro- 
ductiv PSClO-DE column (BPS Separations Ltd., Spennymoor, Co. 
Durham, UK) equilibrated in 0.1 M Tris-HCl buffer, pH 8.5. After 
extensive washing, the recombinant protein was eluted by a linear 
gradient (50 ml each) of O-0.8 M NaCl in the same buffer. 
2.4. Analytical measurements 
*Corresponding author. Fax: (44) (222) 874116. 
SDS-PAGE was performed by the method of Laemmli [6] and gels 
were stained with Coomassie blue. Edman degradation was performed 
after blotting samples onto polyvinylidene difluoride (PVDF) as de- 
scribed previously [4]. Derivation of kinetic parameters (K,,,, k,,,) for the 
hydrolysis of synthetic chromogenic substrates and K, values for the 
interaction of naturally-occurring and synthetic inhibitors was carried 
out as described previously [7j. 
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3. Results and discussion 
In common with all other known aspartic proteinases [8], 
Plasmepsin II is produced in the form of a precursor; but in 
contrast to other archetypal zymogens, the propart region of 
the Plasmodium proteinase(s) is much longer (>lOO residues) 
[3,41. 
Table 1 
Kinetic constants for the cleavage ofchromogenic substrates by recom- 
binant Plasmepsin II 
Ala-Leu-Glu-Arg-Thr-Phe* Nph-Ser- 
Since precursors of mammalian and fungal aspartic pro- 
teinases with propart segments of only 45-50 residues have 
been expressed successfully in high yields [9,10], attempts were 
made to produce Plasmepsin II initially in the form of a precur- 
sor with a propart segment of approximately this length. The 
translated sequence at the N-terminus of the plasmid con- 
structed was 
Phe-Pro-Thr 110 3.8 35 
Lys-Pro-Ile-Val-Phe * Nph-Arg-Leu IO 1.6 160 
Lys-Pro-Ile-Lys-Phe * Nph-Arg-Leu n.d. 0.04 
Measurements made in 0.1 M sodium citrate buffer, pH 4.7; n.d. = not 
determined. 
which is coincident with the sequence predicted for recombi- 
nant, mature Plasmepsin II from the nucleotide sequence, as 
described previously [4]. 
Met-Ala-Ser-Met-Thr-Gly-Gly-Gln-Gln-Met-Gly-Arg-Gly- 
Ser-Glu-His-Leu-Thr-Ile-Gly- 
in which the first 13 residues were derived from the plasmid and 
the authentic sequence of the Plasmodium protein begins with 
the sequence Ser-Glu-His-Leu-Thr-Ile-Gly-. 
This construct thus omitted the first 76 residues of the full- 
length proPlasmepsin II described previously [4]. 
Aliquots of this recombinant material were acidified to pH 
4.7 and incubated at room temperature. Samples were removed 
at appropriate intervals and analysed by SDS-PAGE (Fig. 1) 
to monitor the autoactivation of the precursor to mature en- 
zyme. This conversion was essentially complete after 40 min but 
was prevented completely by inclusion of pepstatin (final con- 
centration of 100 nM) during the incubation (Lane 8, Fig. 1). 
The truncated precursor which accumulated in an insoluble 
form in E. coli was solubilised, re-folded and concentrated as 
described in section 2, using a protocol adapted from those 
applied successfully to zymogens of other aspartic proteinases 
reported previously [9,10,11]. The resultant material obtained 
after DEAE-chromatography consisted primarily of a band 
that migrated on SDS-PAGE with an apparent mol.wt. of -43K 
(Labelled pro; Lane 1, Fig. 1). Through 20 cycles, the sequence 
of this band determined from a PVDF blot, was found to be 
The N-terminal sequence of the resultant enzyme was also 
determined, after blotting onto PVDF, and was found to be 
Leu-Asn-Ser-Gly-Leu-Thr-Lys-Thr-Asn-Tyr-Leu-Gly-Ser- 
In this way, highly purified preparations of Plasmepsin II were 
obtained. The yield of purified, active enzyme was estimated to 
be -20 mg/l of culture. 
Gly-Arg-Gly-Ser-Glu-His-Leu-Thr-Ile-Gly-Phe-Lys-Val- 
Glu- Asn-Ala-Hi s-Asp-Arg-Ile - 
This corresponds to the authentic N-terminus of the (trun- 
cated) precursor protein, preceded by three residues of the gene 
10 leader peptide (see above). A minor, accompanying band 
(labelled mature, Lane 1, Fig. 1) was also subjected to Edman 
degradation after blotting onto PVDF. The sequence eluci- 
dated was 
Leu-Asn-Ser-Gly-Leu-Thr-Lys-Thr-Asn-Tyr-Leu-Gly-Ser- 
Ser-Asn-Asp-As n-Ile-Glu-Leu-Val-Asp-Phe-Gln-Asn- 
The recombinant enzyme thus produced is longer by 12 res- 
idues than its natural counterpart in the form that was analysed 
[2] after purification from isolated food vacuoles. It is not clear 
at present whether the latter truly exists within the food vacuole 
or whether it results artifactually because of N-terminal trim- 
ming during the lengthy procedures that had to be employed 
for purification of the food vacuolar enzyme [2]. Amongst oth- 
ers, an aminopeptidase [12] and a cysteine proteinase in the 
food vacuole [2] have been identified, which could contribute 
to such processing during purification of the natural enzyme. 
The recombinant protein was not exposed to such potential 
hazards. Furthermore, the N-terminal region of the mature 
forms of members of the aspartic proteinase family is known 
to be highly variable, both in content and in length [8]. 
As further confirmation of this, the mature recombinant 
Table 2 
Interaction of Plasmepsin II with various inhibitors 
Inhibitor 
1. D-His-Pro-Phe-His-LeuW [CH,-NH]-Leu-Val-Tyr > 10,000 
2. Pro-His-Pro-Phe-His-Leuy [CH,-NH-Val-Ile-His-Lys > 4,000 
3. Boc-His-Pro-Phe-His-Leuqf [YH-CH,]-Val-Ile-His 150 
OH 
4. Boc-His-Pro-Phe-His- Sta- Leu-Phe-NH, 1000 
5. Pro-Thr-Glu-Phev [cH,-NH]-Phe-Arg-Glu > 4,000 
6. Lac-Valp Sta-Ala-Sta 100 
7. AC-Val-Val-----Sta-Ala-Sta 0.6* 
8. Iva-Val-ValpSta-Ala-Sta 0.1* 
*Denotes K, values which were calculated using high concentrations of enzyme; this was necessary due to the relatively low k,,, with the substrates 
available. Determined at pH 4.7. 
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Fig. 1. Time course of the conversion of precursor to mature form of Plasmepsin II. Samples of precursor were acidified in 0.1 M sodium citrate 
buffer, pH 4.7, incubated at room temperature and aliquots were removed for analysis by SDS-PAGE at 0, 10, 20, 30, 40, 60, 120 min (lanes 1-7, 
respectively). A separate incubation performed in the presence of 100 nM isovaleryl-pepstatin is depicted in lane 8. 
enzyme was examined for its activity. The initial bond cleaved 
within haemoglobin by the Plasmodium enzymes has been iden- 
tified previously to be that between -Phe33 * Leu34 located in the 
alpha-chain [1,2]. A peptide based on this sequence was syn- 
thesised in which the Leu residue was replaced in the PI, posi- 
tion by the chromogenic reporter residue, p-nitrophenylalan- 
ine, as described previously [7]. The hydrolysis at pH 4.7 of the 
resultant peptide 
Ala-Leu-Glu-Arg-Thr-Phe*Nph-Ser-Phe-Pro-Thr 
by the recombinant Plasmepsin II was monitored spectro- 
photometrically and the kinetic parameters derived (Table 1) 
indicate that this substrate was effectively cleaved. The K,,, 
value is directly comparable to the values derived previously for 
hydrolysis of equivalent peptides by a number of other aspartic 
proteinases (recombinant and naturally occurring), of human, 
animal and fungal origin [7]. However, the k,,, value obtained 
is at the low end of this range of values. 
In order to ascertain whether Plasmepsin II was specific for 
Hb as a substrate, its activity was measured towards a second 
synthetic chromogenic peptide (Table l), which is not derived 
from haemoglobin but which has been shown previously to be 
hydrolysed readily by the human enzymes, cathepsin D [13] and 
cathepsin E [14]. The K,,, value measured for this substrate with 
Plasmepsin II was considerably better than that for the peptide 
derived from haemoglobin (Table 1). Indeed, the specificity 
constant (kCat/Km) determined for this second substrate was 
almost 5-fold better than that measured for the haemoglobin- 
derived sequence. However, when the Val residue in the P, 
position was substituted by a Lys, the resultant peptide was 
almost resistant to hydrolysis by Plasmepsin II (Table 1). 
At the amino acid level, Plasmepsin II shows about 35% 
identity in sequence to human renin, cathepsin D and cathepsin 
E. In order to investigate this further, the susceptibility of 
Plasmepsin II to inhibition by a series of compounds, including 
some which are highly specific for renin, was examined (Table 
2). The Plasmodium enzyme was not affected by inhibitors 1, 
2 and 4 which are highly specific for renin, whilst compound 
3, although certainly a potent renin inhibitor, has been shown 
previously [15] to be non-selective. Compound 6 is a water- 
soluble derivative of pepstatin, that inhibited Plasmepsin II 
with an I& of 100 nM, a value that is comparable to that 
derived previously for human cathepsin D [16]. As might be 
expected of an aspartic proteinase, Plasmepsin II was potently 
inhibited by the poorly water-soluble acetyl (compound 7) and 
isovaleryl (compound 8) pepstatins, which have been shown 
previously to have varying potencies towards aspartic pro- 
teinases of mammalian, fungal [17] and retroviral [18] origin. 
Plasmepsin II is thus not a highly-specific aspartic proteinase 
like renin; since it is able to hydrolyse competently a substrate 
with a sequence unrelated to that of haemoglobin, it would 
appear to be a more degenerate nzyme, akin to cathepsin D 
or cathepsin E. Its inability to cleave a substrate with a P, Lys 
residue indicates behaviour comparable to that of cathepsin D 
1131. 
The precursor and mature forms of Plasmepsin II were both 
produced in sufficiently high amounts to enable attempts at 
crystallisation now to be made with a view to elucidation of the 
3-dimensional structure of the proteins. Such information, cou- 
pled with a mutagenesis programme, should enable evaluation 
of structure/function relationships in this important enzyme, 
together with the development of selective inhibitors that might 
have considerable therapeutic potential in combatting malaria. 
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